Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

MabThera now available for non-Hodgkin's lymphoma in the U.K.

July 23, 1998

FDA grants second orphan drug designation for ImmTher

July 20, 1998

Medarex begins clinical trials of Bispecific antibody for cancer

July 20, 1998

Phase II trial of Avicine in prostate cancer announced

July 17, 1998

AltaRex initiates second phase II trial of OvaRex

July 16, 1998

Theragyn phase III testing will begin in U.K.

July 13, 1998

Regressin holds promise for a wide range of cancers, new data indicates

July 13, 1998

IL-4 fusion toxin shows potent antitumor activity in murine model of KS

July 10, 1998

NeoPharm scales up IL13-PE38QQR manufacturing

July 10, 1998

GOG will evaluate Avax Technologies' ovarian cancer vaccine in phase I/II study

July 6, 1998

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
AA meeting of minds as PTC, Novartis push votoplam in HD
BioWorld
What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...